237 related articles for article (PubMed ID: 31122263)
1. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Khorashad JS; Eiring AM; Mason CC; Gantz KC; Bowler AD; Redwine HM; Yu F; Kraft IL; Pomicter AD; Reynolds KR; Iovino AJ; Zabriskie MS; Heaton WL; Tantravahi SK; Kauffman M; Shacham S; Chenchik A; Bonneau K; Ullman KS; O'Hare T; Deininger MW
Blood; 2015 Mar; 125(11):1772-81. PubMed ID: 25573989
[TBL] [Abstract][Full Text] [Related]
4. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
Okabe S; Moriyama M; Gotoh A
Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
[TBL] [Abstract][Full Text] [Related]
5. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Eiring AM; Khorashad JS; Anderson DJ; Yu F; Redwine HM; Mason CC; Reynolds KR; Clair PM; Gantz KC; Zhang TY; Pomicter AD; Kraft IL; Bowler AD; Johnson K; Partlin MM; O'Hare T; Deininger MW
Leukemia; 2015 Dec; 29(12):2328-37. PubMed ID: 26202934
[TBL] [Abstract][Full Text] [Related]
6. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
[TBL] [Abstract][Full Text] [Related]
8. PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.
Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Thangavel S; Alobaisi K; Diaz R; Begum R; Haqawi W; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Mol Oncol; 2024 Mar; 18(3):691-706. PubMed ID: 38361222
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib.
Klaihmon P; Lorthongpanich C; Kheolamai P; Saisaard W; Issaragrisil S
Sci Rep; 2024 Feb; 14(1):3993. PubMed ID: 38368446
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.
Hekmatshoar Y; Karadag Gurel A; Ozkan T; Rahbar Saadat Y; Koc A; Karabay AZ; Bozkurt S; Sunguroglu A
Adv Med Sci; 2023 Sep; 68(2):238-248. PubMed ID: 37421850
[TBL] [Abstract][Full Text] [Related]
11. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
[TBL] [Abstract][Full Text] [Related]
12. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
Wu A; Liu X; Fruhstorfer C; Jiang X
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279
[TBL] [Abstract][Full Text] [Related]
13. miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34
Zhang X; Ma W; Xue W; Wang Y; Chen P; Li Q; Li YY; Hu X; Zhao Y; Zhou H
Cell Mol Life Sci; 2023 Dec; 81(1):10. PubMed ID: 38103082
[TBL] [Abstract][Full Text] [Related]
14. Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapies.
Karagiannis TC; Wall M; Ververis K; Pitsillou E; Tortorella SM; Wood PA; Rafehi H; Khurana I; Maxwell SS; Hung A; Vongsvivut J; El-Osta A
Cell Mol Life Sci; 2023 Aug; 80(9):248. PubMed ID: 37578596
[TBL] [Abstract][Full Text] [Related]
15. A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells.
Zhang X; Wang Y; Lu J; Xiao L; Chen H; Li Q; Li YY; Xu P; Ruan C; Zhou H; Zhao Y
Cell Mol Biol Lett; 2023 Oct; 28(1):83. PubMed ID: 37864206
[TBL] [Abstract][Full Text] [Related]
16. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
Ye Y; Yang X; Li F; Liu W; Zhang W; Huang Z
Animal Model Exp Med; 2024 Apr; 7(2):136-144. PubMed ID: 36300552
[TBL] [Abstract][Full Text] [Related]
17. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
Park CS; Lewis AH; Chen TJ; Bridges CS; Shen Y; Suppipat K; Puppi M; Tomolonis JA; Pang PD; Mistretta TA; Ma L; Green MR; Rau R; Lacorazza HD
Blood; 2019 Nov; 134(22):1960-1972. PubMed ID: 31515251
[TBL] [Abstract][Full Text] [Related]
18. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
[TBL] [Abstract][Full Text] [Related]
19. The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia.
Deręgowska A; Pępek M; Solarska I; Machnicki MM; Pruszczyk K; Dudziński M; Niesiobędzka-Krężel J; Seferyńska I; Sawicki W; Wnuk M; Stokłosa T
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7103-7112. PubMed ID: 36871092
[TBL] [Abstract][Full Text] [Related]
20. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.
Cerny-Reiterer S; Ghanim V; Hoermann G; Aichberger KJ; Herrmann H; Muellauer L; Repa A; Sillaber C; Walls AF; Mayerhofer M; Valent P
Neoplasia; 2012 Jul; 14(7):572-84. PubMed ID: 22904675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]